Global biotechnology company CSL Limited has launched a public tender offer to acquire all publicly held Vifor Pharma shares.
“Vifor Pharma enhances CSL’s patient focus and ability to protect the health of those facing a range of rare and serious medical conditions. It brings an outstanding team and a leading portfolio of products across Nephrology, Dialysis and Iron Deficiency therapies and a proven partnering and business development and licensing strategy. Vifor Pharma will also expand our presence in the rapidly growing nephrology market, while giving us the opportunity to leverage our complementary scientific expertise” said Paul Perreault, Chief Executive Officer and Managing Director of CSL.
Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma, said: “The offer provides an excellent strategic opportunity for Vifor Pharma to optimise future market opportunities from a from a position of strength and to create substantial value for all stakeholders.”
